Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer
American Journal of Cancer Research · 2024 · 14 (8) · 3962-3975
DOI: 10.62347/myza2640 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Cancer Research, 2024. Verfasst von Mengjie Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Science, Shenzhen Yantian District People's Hospital Shenzhen 518081, Guangdong, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Science, Shenzhen Yantian District People's Hospital Shenzhen 518081, Guangdong, China.
Zitieren
APA
Luo, M., Li, Q., Gu, Q., & Zhang, C. (2024). Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer. American Journal of Cancer Research, 14(8), 3962-3975. https://doi.org/10.62347/myza2640
Vancouver
Luo M, Li Q, Gu Q, Zhang C. Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer. American Journal of Cancer Research. 2024;14(8):3962-3975. doi:10.62347/myza2640
BibTeX
@article{Luo2024,
author = {Luo, Mengjie and Li, Qi and Gu, Qingdan and Zhang, Chunlei},
title = {Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer},
journal = {American Journal of Cancer Research},
year = {2024},
volume = {14},
number = {8},
pages = {3962--3975},
doi = {10.62347/myza2640}
}
EUVIMED